{"organizations": [], "uuid": "39ab3db6db18611084900f07626efe52ec852141", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180307.html", "section_title": "Archive News &amp; Video for Wednesday, 07 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-aevi-genomic-medicine-expands-coll/brief-aevi-genomic-medicine-expands-collaboration-with-kyowa-hakko-kirin-co-idUSFWN1QP0KR", "country": "US", "domain_rank": 408, "title": "BRIEF-Aevi Genomic Medicine Expands Collaboration With Kyowa Hakko Kirin Co", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.088, "site_type": "news", "published": "2018-03-07T21:20:00.000+02:00", "replies_count": 0, "uuid": "39ab3db6db18611084900f07626efe52ec852141"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-aevi-genomic-medicine-expands-coll/brief-aevi-genomic-medicine-expands-collaboration-with-kyowa-hakko-kirin-co-idUSFWN1QP0KR", "ord_in_thread": 0, "title": "BRIEF-Aevi Genomic Medicine Expands Collaboration With Kyowa Hakko Kirin Co", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-aevi genomic medicine expands collaboration with kyowa hakko kirin co", "sentiment": "negative"}, {"name": "aevi genomic medicine inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "kyowa hakko kirin co ltd", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 7 (Reuters) - Aevi Genomic Medicine Inc:\n* AEVI GENOMIC MEDICINE INC - EXPANDED COLLABORATION WITH KYOWA HAKKO KIRIN CO LTD\n* AEVI GENOMIC MEDICINE - SIGNING OF OPTION AGREEMENT FOR EARLY STAGE MONOCLONAL ANTIBODY PROGRAM IN AN ULTRA-ORPHAN PEDIATRIC INDICATION\n* AEVI GENOMIC MEDICINE INC - FINANCIAL AND OTHER TERMS OF DEAL WERE NOT DISCLOSED Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-07T21:20:00.000+02:00", "crawled": "2018-03-08T17:34:31.012+02:00", "highlightTitle": ""}